Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472428 | 0.99 | TDP1 (0.40) | HDAC3TUBB4ATUBBTUBA3CHDAC4 | |
| SCHEMBL7468973 | 0.85 | MAPT (0.39) | — | |
| SCHEMBL7467871 | 0.84 | CHRM2 (0.40) | POLBHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7466742 | 0.84 | CHRM2 (0.40) | POLBHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7477559 | 0.83 | CHRM2 (0.42) | POLBHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7464083 | 0.83 | TDP1 (0.43) | HDAC3TUBB4ATUBBTUBA3CHDAC4 | |
| SCHEMBL7469938 | 0.82 | PARK7 (0.35) | — | |
| SCHEMBL7468519 | 0.81 | MEN1 (0.39) | HDAC3TUBB4ATUBBTUBA3CHDAC4 | |
| SCHEMBL7470345 | 0.78 | HTR1A (0.66) | TDP1L3MBTL1 | |
| SCHEMBL7467468 | 0.76 | HTR1A (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966440-B1 | METHOD OF PRODUCTION AND METHOD OF SEPARATION OF 2,4'-DIPYRIDYL DERIVATIVES AND METHODS OF PRODUCTION OF BENZOXAZEPINE DERIVATIVES AND SALTS THEREOF | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-6624308-B2 | Cross coupling of 2-halopyridine and 4-halopyridine using nickel complex catalyst | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-09-23 | — | — | US | disclosed |
| US-20030125547-A1 | Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-0755930-B1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LTD (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6337397-B1 | A BENZOXAZEPINE DERIVATIVE FOR TREATMENT OF ANXIETY NEUROSIS, PHOBIAS, OBSESSIVE-COMPULSIVE DISORDERS, SCHIZOPHRENIA, POST-CARDIAC TRAUMA STRESS DISORDERS, DEPRESSION DISORDERS, PSYCHOSOMATIC DISORDERS AND OTHER PSYCHONEUROTIC DISORDERS, | SUNTORY LIMITED (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6187769-B1 | Benzoxazepine derivatives and their salts and medicaments containing the same | SUNTORY LIMITED (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6096884-A | CROSS COUPLING REACTION OF A 2-HALOPYRIDINE DERIVATIVE AND A 4-HALOPYRIDINE USING A NICKEL COMPLEX CATALYST | SUNTORY LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0755930-A1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125547-A1 | Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof | WIZ, HELZ, HPD | POLB 2120/4885PKM 2826/4885TSHR 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.